Top

Impact of TKI discontinuation in CML patients who have previously restarted TKI following allogeneic SCT

Chronic Malignancies Working Party (CMWP)
Study type:
Retrospective Studies
Study number:
42201053
Type of treatment:
Allogeneic
Diseases:
Chronic Myeloid Leukaemia (CML)
Short title:
Outcome after discontinuation TKI after allo
Primary objective:
Treatment-free remission/survival without molecular relapse, cytogenetic or morphological relapse
Key inclusion criteria:
- diagnosis: CML all phases
- type of transplant: all conditioning
- age >18 years
- period analysed: 2004-2022
- stem cell source: all
- inclusion criteria: patients with CML restarting on TKI following allo-SCT and subsequently discontinuing TKI at any time point following allo-SCT
Country:
All EBMT member countries
Principal investigator:
Hugues de Lavallade
EBMT Study coordinator:
Joe Tuffnell
Study coordinator email:
cmwp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Study Specific Questionnaire (MED-C)
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
Investigators
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No

Privacy notices

Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)

Data Protection Impact Assessments

Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results